10-Q: Vivos Therapeutics Q1 2026 Financial Results

Vivos Therapeutics reports Q1 2026 revenue of $5.1 million, driven by its new medical-provider focused business model, while facing ongoing liquidity and Nasdaq compliance challenges.

Summary

• Reported total revenue of $5.1 million for Q1 2026, a 70% increase compared to $3.0 million in Q1 2025.
• Net loss for the quarter was $7.75 million, compared to a net loss of $3.86 million in the prior year period.
• Service revenue grew significantly to $3.7 million, largely due to the acquisition of The Sleep Center of Nevada (SCN).
• Product revenue declined to $1.4 million from $1.8 million in Q1 2025, reflecting a strategic shift away from the legacy dentist-focused model.
• Cash and cash equivalents stood at $2.1 million as of March 31, 2026.
• The company is currently not in compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk situation; while revenue is growing due to acquisitions, the company is burning cash, faces a potential Nasdaq delisting, and has raised substantial doubt about its ability to continue as a going concern.

Positives

• Total revenue increased by 70% year-over-year to $5.1 million.
• Gross profit improved to $3.1 million from $1.5 million in Q1 2025.
• Gross margin expanded to 60% in Q1 2026, up from 50% in the same period last year.
• Successfully raised $6.8 million in gross proceeds through equity financing transactions during the first quarter of 2026.

Negatives

• Net loss widened to $7.75 million from $3.86 million in Q1 2025.
• Operating expenses increased significantly to $9.7 million, up from $5.4 million in Q1 2025.
• Product revenue decreased by 21% year-over-year.
• The company has an accumulated deficit of approximately $133 million as of March 31, 2026.

Risks

• Substantial doubt regarding the ability to continue as a going concern due to recurring losses and insufficient cash to fund operations for the next twelve months.
• Risk of Nasdaq delisting due to failure to meet the minimum stockholders' equity requirement.
• Dependence on the success of the new, unproven medical-provider focused sales and distribution model.
• Challenges in integrating the SCN business, including staffing, accounting, and insurance reimbursement.
• Significant indebtedness incurred to finance the SCN acquisition.
• Potential for the Stanford University clinical study to remain on hold indefinitely or fail to meet endpoints.

Future Outlook

The company aims to increase revenue through its new medical-provider focused strategic alliance and acquisition model, specifically leveraging the SCN acquisition. It plans to seek additional financing to fund operations and regain Nasdaq compliance, though there is no assurance of success.

Management Comments

• Management acknowledges that current cash levels are insufficient to fund operations for the next twelve months.
• Management is actively evaluating ways to restructure senior debt to reduce debt service obligations.
• Management believes the SCN acquisition will ultimately allow the company to achieve positive cash flows.

Industry Context

StockSavvy.ai notes that Vivos is attempting a difficult pivot from a B2B dental training model to a direct-to-patient medical service model. This transition is occurring amidst a broader industry trend of consolidating sleep diagnostic and treatment services, but Vivos faces significant execution risk and capital constraints compared to more established medical device competitors.

Comparison to Industry Standards

• Vivos's reliance on high-cost debt financing for acquisitions is aggressive compared to industry peers with stronger balance sheets.
• The company's negative stockholders' equity position places it at a disadvantage relative to standard industry benchmarks for publicly traded medical technology firms.
• The pivot to a medical-provider focused model aligns with industry trends toward integrated care, but the company's small scale and limited cash reserves make execution significantly more challenging than for larger, diversified healthcare providers.

Legal Proceedings

• Resolved litigation with Ortho-Tain, Inc. via a confidential settlement agreement on March 13, 2026.

Related Party Transactions

• The company maintains office space leases with entities controlled by Dr. Prabhu Rachakonda, an employee and founder of SCN.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity raises.
• Nasdaq listing status is at risk, which could impact stock liquidity and valuation.
• Employees and creditors face uncertainty regarding the company's long-term financial viability.

Next Steps

• Submit a compliance plan to Nasdaq by June 1, 2026.
• Continue efforts to integrate SCN operations and improve revenue generation.
• Seek additional financing to fund operations and satisfy Nasdaq requirements.

Key Dates

Recommendation

The combination of a widening net loss, going concern warning, and Nasdaq delisting risk makes this a highly speculative and dangerous investment for institutional or conservative investors.

Keywords

Vivos Therapeutics, VVOS, Obstructive Sleep Apnea, Medical Device, Sleep Center of Nevada, Nasdaq Compliance, Oral Appliances